BeiGene celebrates profit milestone on soaring drug sales
Buoyed by U.S. demand for its blockbuster cancer drug, the Chinese biopharma firm has delivered its first quarterly profit on a GAAP basis Key Takeaways: Global sales of the company’s…
FAST NEWS: BeiGene Loss Narrows on Brisk Sales for Core Products
The latest: Cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) announced Monday its revenue rose 20.4% last year to $1.42 billion, thanks to big increases from its two core products,…
FAST NEWS: I-Mab to Move Ahead With Dual Listing in Hong Kong
The latest: U.S.-listed cancer drug developer I-Mab (IMAB.US) announced its board has approved a motion to pursue a listing on the Hong Kong Stock Exchange. The board also authorized the company's…
Pandemic Accelerates China’s Drive Into mRNA Treatments
Messenger RNA-based technology that is highly effective in preventing Covid-19 can also be used for treatment of other diseases Key points: High efficacy rates in preventing Covid-19 spark rush by…
RELATED ARTICLES
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- RNA drug developer Ribo Life targets fresh funding channel
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Investors cheer Akeso’s revenue milestone, even as it returns to the red
9926.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- Innogen Pharma jostles for a slice of the weight-loss market
